A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PHD / prolyl hydroxylase domain-containing protein

[Related PubMed/MEDLINE]
Total Number of Papers: 24
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PHD  (>> Co-occurring Abbreviation)
Long Form:   prolyl hydroxylase domain-containing protein
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia. EPO
2018 Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease. AAA, HIF-1, mRNA, PPE
2018 Hypoxia-sensitive pathways in intestinal inflammation. HIF, IBD
2016 HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. ESAs, HIF
2015 A role for vaccinia virus protein C16 in reprogramming cellular energy metabolism. HIF, VACV
2014 Anaerobic respiration sustains mitochondrial membrane potential in a prolyl hydroxylase pathway-activated cancer cell line in a hypoxic microenvironment. AF, DMOG, GFP
2014 Neovascularization induced by hypoxia inducible transcription factor is associated with the improvement of cardiac dysfunction in experimental autoimmune myocarditis. EAM, HIF
2013 A mechanism for induction of a hypoxic response by vaccinia virus. HIF, VACV, VEGF
2013 Inhibition of prolyl hydroxylase domain-containing protein on hypertension/renal injury induced by high salt diet and nitric oxide withdrawal. HIF-1alpha, L-NNA
10  2013 Prolyl-hydroxylase inhibition preserves endothelial cell function in a rat model of vascular ischemia reperfusion injury. HIF, IR, VSMCs
11  2013 Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. ESA, HIF
12  2012 Activation of the prolyl-hydroxylase oxygen-sensing signal cascade leads to AMPK activation in cardiomyocytes. AMPK, CaMKK, PHI, RNAi
13  2012 Hypoxia-inducible factor as a therapeutic target for cardioprotection. HIF, VHL
14  2012 Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. EPO, EPOR, HIF, rhEPO
15  2012 The updated biology of hypoxia-inducible factor. HIF
16  2011 Inhibition of prolyl hydroxylase domain-containing protein downregulates vascular angiotensin II type 1 receptor. ---
17  2011 Studies on the reaction of nitric oxide with the hypoxia-inducible factor prolyl hydroxylase domain 2 (EGLN1). HIF
18  2010 Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. ---
19  2010 Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. ESAs, HIF
20  2007 Prolyl hydroxylase inhibitor treatment confers whole-animal hypoxia tolerance. EPO, PHI
21  2006 Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS. ATP, DFO, EDHB, L-NAME, NO, ROS
22  2006 Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. EPO, FIH, HIF
23  2006 Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. HIF, MI, P4-HI, P4H
24  2003 Activation of the prolyl hydroxylase oxygen-sensor results in induction of GLUT1, heme oxygenase-1, and nitric-oxide synthase proteins and confers protection from metabolic inhibition to cardiomyocytes. ---